Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Imaging | 80 | 2023 | 3444 | 5.170 |
Why?
|
Contrast Media | 51 | 2023 | 1090 | 4.990 |
Why?
|
Prostatic Neoplasms | 35 | 2023 | 1768 | 3.320 |
Why?
|
Image Enhancement | 20 | 2021 | 567 | 2.050 |
Why?
|
Gadolinium DTPA | 16 | 2017 | 264 | 1.520 |
Why?
|
Algorithms | 11 | 2018 | 1875 | 1.300 |
Why?
|
Models, Theoretical | 9 | 2018 | 491 | 1.230 |
Why?
|
Image Interpretation, Computer-Assisted | 13 | 2019 | 685 | 1.130 |
Why?
|
Ultrasonic Therapy | 6 | 2012 | 34 | 1.060 |
Why?
|
Prostate | 11 | 2023 | 393 | 1.040 |
Why?
|
Signal-To-Noise Ratio | 4 | 2021 | 103 | 1.030 |
Why?
|
Mammary Glands, Animal | 8 | 2020 | 80 | 1.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 12 | 2023 | 302 | 1.020 |
Why?
|
Mammary Neoplasms, Experimental | 7 | 2015 | 125 | 0.940 |
Why?
|
Arteries | 4 | 2021 | 180 | 0.920 |
Why?
|
Ultrasonics | 7 | 2012 | 39 | 0.870 |
Why?
|
Computer Simulation | 11 | 2021 | 1097 | 0.870 |
Why?
|
Mammary Neoplasms, Animal | 4 | 2020 | 57 | 0.780 |
Why?
|
Breast Neoplasms | 18 | 2023 | 3003 | 0.760 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 115 | 0.760 |
Why?
|
Image Processing, Computer-Assisted | 14 | 2022 | 1239 | 0.730 |
Why?
|
Reproducibility of Results | 22 | 2021 | 2753 | 0.730 |
Why?
|
Muscle, Skeletal | 7 | 2020 | 467 | 0.730 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2014 | 158 | 0.690 |
Why?
|
Models, Biological | 13 | 2015 | 1764 | 0.610 |
Why?
|
Breast | 8 | 2017 | 292 | 0.600 |
Why?
|
Phantoms, Imaging | 5 | 2015 | 448 | 0.590 |
Why?
|
Organometallic Compounds | 4 | 2021 | 134 | 0.590 |
Why?
|
Carcinoma in Situ | 2 | 2015 | 53 | 0.580 |
Why?
|
Animals | 50 | 2023 | 27330 | 0.540 |
Why?
|
Sensitivity and Specificity | 16 | 2023 | 2014 | 0.540 |
Why?
|
Rats | 18 | 2017 | 4041 | 0.530 |
Why?
|
Magnetic Resonance Angiography | 3 | 2020 | 271 | 0.490 |
Why?
|
Male | 44 | 2023 | 42309 | 0.450 |
Why?
|
Hyperthermia, Induced | 5 | 2012 | 73 | 0.440 |
Why?
|
Imaging, Three-Dimensional | 4 | 2020 | 595 | 0.430 |
Why?
|
Neoplasms, Experimental | 2 | 2005 | 269 | 0.420 |
Why?
|
Biomimetic Materials | 1 | 2012 | 24 | 0.400 |
Why?
|
Tumor Hypoxia | 2 | 2022 | 30 | 0.390 |
Why?
|
Neoplasm Transplantation | 6 | 2010 | 397 | 0.390 |
Why?
|
Humans | 70 | 2023 | 89157 | 0.390 |
Why?
|
Abdominal Abscess | 1 | 2011 | 22 | 0.390 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 43 | 0.380 |
Why?
|
Subtraction Technique | 3 | 2009 | 132 | 0.370 |
Why?
|
Mice | 27 | 2023 | 11743 | 0.370 |
Why?
|
Meglumine | 3 | 2021 | 38 | 0.370 |
Why?
|
Middle Aged | 34 | 2023 | 25910 | 0.350 |
Why?
|
Camellia sinensis | 1 | 2009 | 7 | 0.340 |
Why?
|
Angiogenesis Modulating Agents | 1 | 2009 | 4 | 0.340 |
Why?
|
Peripheral Arterial Disease | 2 | 2021 | 94 | 0.330 |
Why?
|
Computed Tomography Angiography | 2 | 2021 | 146 | 0.320 |
Why?
|
Fluorine | 2 | 2005 | 17 | 0.320 |
Why?
|
Neovascularization, Pathologic | 5 | 2015 | 364 | 0.310 |
Why?
|
Diet, High-Fat | 2 | 2020 | 117 | 0.310 |
Why?
|
Fourier Analysis | 5 | 2016 | 126 | 0.310 |
Why?
|
Female | 41 | 2023 | 46078 | 0.310 |
Why?
|
Plant Extracts | 1 | 2009 | 245 | 0.290 |
Why?
|
Carcinogenesis | 2 | 2020 | 211 | 0.280 |
Why?
|
Adipose Tissue | 2 | 2006 | 259 | 0.280 |
Why?
|
Laser Therapy | 2 | 2018 | 149 | 0.280 |
Why?
|
Triple Negative Breast Neoplasms | 2 | 2020 | 152 | 0.280 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2006 | 14 | 0.270 |
Why?
|
Fluorocarbons | 1 | 2005 | 72 | 0.260 |
Why?
|
Ultrasonography | 4 | 2014 | 711 | 0.260 |
Why?
|
Aged | 21 | 2023 | 19119 | 0.250 |
Why?
|
Pilot Projects | 10 | 2021 | 868 | 0.250 |
Why?
|
Echo-Planar Imaging | 5 | 2008 | 52 | 0.250 |
Why?
|
Misonidazole | 2 | 2022 | 17 | 0.240 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2002 | 312 | 0.240 |
Why?
|
Body Water | 3 | 2004 | 35 | 0.240 |
Why?
|
Prostatectomy | 6 | 2023 | 476 | 0.240 |
Why?
|
Gadolinium | 2 | 2018 | 103 | 0.240 |
Why?
|
Muscle Neoplasms | 1 | 2004 | 18 | 0.230 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 414 | 0.230 |
Why?
|
PTEN Phosphohydrolase | 3 | 2023 | 136 | 0.230 |
Why?
|
Myocardium | 1 | 2006 | 571 | 0.220 |
Why?
|
Thorax | 2 | 2000 | 77 | 0.220 |
Why?
|
Neoplasm Invasiveness | 5 | 2020 | 576 | 0.220 |
Why?
|
Mice, Transgenic | 7 | 2018 | 1574 | 0.210 |
Why?
|
Retrospective Studies | 11 | 2023 | 9022 | 0.210 |
Why?
|
Carbon Dioxide | 2 | 2002 | 202 | 0.210 |
Why?
|
Oxygen | 4 | 2021 | 742 | 0.210 |
Why?
|
Water | 4 | 2009 | 283 | 0.200 |
Why?
|
Feasibility Studies | 7 | 2020 | 780 | 0.200 |
Why?
|
Receptor, ErbB-2 | 1 | 2023 | 245 | 0.200 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 121 | 0.190 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2023 | 158 | 0.190 |
Why?
|
Neoplasms | 7 | 2020 | 3037 | 0.190 |
Why?
|
Adult | 20 | 2023 | 26542 | 0.180 |
Why?
|
Rats, Inbred F344 | 4 | 2005 | 154 | 0.180 |
Why?
|
Leg | 1 | 2021 | 140 | 0.180 |
Why?
|
Acoustics | 2 | 1997 | 51 | 0.180 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 374 | 0.180 |
Why?
|
Neoplasm Grading | 4 | 2023 | 372 | 0.170 |
Why?
|
Blood-Brain Barrier | 2 | 2023 | 74 | 0.170 |
Why?
|
Lower Extremity | 1 | 2020 | 87 | 0.170 |
Why?
|
Arterial Occlusive Diseases | 1 | 2020 | 109 | 0.160 |
Why?
|
Electromagnetic Fields | 1 | 1999 | 26 | 0.160 |
Why?
|
Microvessels | 2 | 2009 | 69 | 0.160 |
Why?
|
Ischemia | 1 | 2021 | 251 | 0.160 |
Why?
|
Disease Models, Animal | 8 | 2020 | 2363 | 0.160 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 2658 | 0.160 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2018 | 36 | 0.160 |
Why?
|
Dietary Sugars | 1 | 2018 | 8 | 0.150 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.150 |
Why?
|
Diet, Fat-Restricted | 1 | 2018 | 30 | 0.150 |
Why?
|
Information Storage and Retrieval | 2 | 2010 | 121 | 0.150 |
Why?
|
Brain Neoplasms | 2 | 2014 | 781 | 0.150 |
Why?
|
Prostatic Hyperplasia | 1 | 2019 | 91 | 0.150 |
Why?
|
Prospective Studies | 6 | 2018 | 4281 | 0.150 |
Why?
|
Hindlimb | 3 | 2010 | 95 | 0.150 |
Why?
|
Pulse Wave Analysis | 1 | 2017 | 10 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2020 | 327 | 0.150 |
Why?
|
Androgen Antagonists | 3 | 2023 | 154 | 0.150 |
Why?
|
Wrist | 1 | 2017 | 22 | 0.150 |
Why?
|
Therapy, Computer-Assisted | 2 | 1995 | 17 | 0.150 |
Why?
|
Fatty Acids | 1 | 2018 | 134 | 0.140 |
Why?
|
Oxides | 3 | 2002 | 43 | 0.140 |
Why?
|
Time Factors | 7 | 2012 | 5331 | 0.140 |
Why?
|
Dietary Fats | 1 | 2017 | 135 | 0.140 |
Why?
|
Iron | 3 | 2002 | 168 | 0.140 |
Why?
|
Immunohistochemistry | 4 | 2016 | 1798 | 0.130 |
Why?
|
Gastrointestinal Microbiome | 1 | 2023 | 504 | 0.130 |
Why?
|
Durapatite | 1 | 2015 | 28 | 0.130 |
Why?
|
Biopsy | 6 | 2019 | 1182 | 0.130 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 1596 | 0.130 |
Why?
|
Observer Variation | 2 | 2021 | 610 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 1096 | 0.130 |
Why?
|
ROC Curve | 5 | 2018 | 781 | 0.120 |
Why?
|
Evaluation Studies as Topic | 3 | 2006 | 270 | 0.120 |
Why?
|
Metal Nanoparticles | 1 | 2014 | 31 | 0.120 |
Why?
|
Temperature | 4 | 1999 | 400 | 0.120 |
Why?
|
Kinetics | 5 | 2023 | 1528 | 0.120 |
Why?
|
Calcium Oxalate | 1 | 2015 | 186 | 0.120 |
Why?
|
Gold | 1 | 2014 | 41 | 0.120 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2014 | 116 | 0.110 |
Why?
|
Reference Values | 2 | 2015 | 661 | 0.110 |
Why?
|
Doxorubicin | 1 | 2014 | 298 | 0.110 |
Why?
|
Crohn Disease | 2 | 2011 | 758 | 0.110 |
Why?
|
Oncolytic Virotherapy | 1 | 2013 | 42 | 0.110 |
Why?
|
Thermometers | 3 | 1999 | 6 | 0.110 |
Why?
|
Brain | 2 | 2003 | 2281 | 0.110 |
Why?
|
Models, Anatomic | 2 | 1998 | 91 | 0.110 |
Why?
|
Manganese Compounds | 1 | 2012 | 5 | 0.110 |
Why?
|
Neural Stem Cells | 1 | 2013 | 58 | 0.110 |
Why?
|
Cell Line, Tumor | 4 | 2023 | 2553 | 0.110 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2013 | 79 | 0.100 |
Why?
|
Disease Progression | 2 | 2014 | 1488 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 267 | 0.100 |
Why?
|
Metabolic Clearance Rate | 4 | 2015 | 120 | 0.100 |
Why?
|
Transducers | 3 | 1997 | 42 | 0.100 |
Why?
|
Chlorides | 1 | 2012 | 103 | 0.100 |
Why?
|
Tumor Cells, Cultured | 3 | 2004 | 1057 | 0.100 |
Why?
|
Niacinamide | 1 | 2012 | 116 | 0.100 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 188 | 0.100 |
Why?
|
Scattering, Radiation | 1 | 1992 | 116 | 0.100 |
Why?
|
Phenylurea Compounds | 1 | 2012 | 114 | 0.100 |
Why?
|
Glioma | 1 | 2014 | 293 | 0.100 |
Why?
|
Proteomics | 2 | 2023 | 230 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2015 | 548 | 0.100 |
Why?
|
Tissue Culture Techniques | 1 | 2011 | 81 | 0.100 |
Why?
|
Ascites | 1 | 2011 | 56 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2011 | 233 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 306 | 0.090 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 285 | 0.090 |
Why?
|
Blood Vessels | 1 | 2011 | 94 | 0.090 |
Why?
|
Glioblastoma | 1 | 2013 | 265 | 0.090 |
Why?
|
Diffusion | 3 | 2013 | 93 | 0.090 |
Why?
|
X-Ray Microtomography | 1 | 2011 | 89 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 711 | 0.090 |
Why?
|
Mice, Knockout | 1 | 2015 | 1990 | 0.090 |
Why?
|
Swine | 1 | 2012 | 581 | 0.090 |
Why?
|
Macrophages | 2 | 2023 | 571 | 0.090 |
Why?
|
Injections | 3 | 2017 | 116 | 0.090 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 479 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 317 | 0.090 |
Why?
|
Glucose | 1 | 2012 | 630 | 0.090 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 336 | 0.090 |
Why?
|
Radiation Dosage | 2 | 2021 | 226 | 0.080 |
Why?
|
Electron Spin Resonance Spectroscopy | 2 | 2022 | 317 | 0.080 |
Why?
|
Extracellular Space | 1 | 2009 | 92 | 0.080 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2009 | 6 | 0.080 |
Why?
|
Perfusion Imaging | 1 | 2009 | 50 | 0.080 |
Why?
|
Intestine, Small | 1 | 2011 | 299 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2009 | 84 | 0.080 |
Why?
|
Insulin-Secreting Cells | 1 | 2012 | 404 | 0.080 |
Why?
|
Aged, 80 and over | 4 | 2017 | 6794 | 0.080 |
Why?
|
Breast Diseases | 2 | 2011 | 100 | 0.080 |
Why?
|
Artifacts | 2 | 2015 | 245 | 0.080 |
Why?
|
Mice, Nude | 4 | 2013 | 814 | 0.080 |
Why?
|
Leiomyoma | 1 | 2012 | 200 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 604 | 0.080 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2006 | 202 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2012 | 245 | 0.070 |
Why?
|
Tumor Burden | 2 | 2020 | 308 | 0.070 |
Why?
|
Ferrosoferric Oxide | 3 | 2002 | 19 | 0.070 |
Why?
|
Magnetite Nanoparticles | 3 | 2002 | 27 | 0.070 |
Why?
|
Dextrans | 3 | 2002 | 79 | 0.070 |
Why?
|
Equipment Design | 2 | 2006 | 415 | 0.070 |
Why?
|
Colitis | 1 | 2010 | 244 | 0.070 |
Why?
|
Protons | 2 | 2008 | 101 | 0.070 |
Why?
|
Materials Testing | 1 | 2006 | 93 | 0.070 |
Why?
|
Genetic Therapy | 1 | 2009 | 370 | 0.070 |
Why?
|
Hypoxia | 2 | 2022 | 650 | 0.070 |
Why?
|
Emulsions | 1 | 2005 | 19 | 0.070 |
Why?
|
Hot Temperature | 2 | 2014 | 208 | 0.070 |
Why?
|
Necrosis | 2 | 1996 | 209 | 0.060 |
Why?
|
Area Under Curve | 3 | 2011 | 337 | 0.060 |
Why?
|
Carcinoma | 1 | 2008 | 443 | 0.060 |
Why?
|
Spin Labels | 2 | 2015 | 106 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 981 | 0.060 |
Why?
|
Biophysical Phenomena | 2 | 1995 | 124 | 0.060 |
Why?
|
Biophysics | 2 | 1995 | 153 | 0.060 |
Why?
|
Lactates | 1 | 2023 | 36 | 0.060 |
Why?
|
Molecular Weight | 1 | 2004 | 331 | 0.060 |
Why?
|
Lead | 1 | 2023 | 26 | 0.060 |
Why?
|
Phagocytosis | 1 | 2023 | 86 | 0.060 |
Why?
|
General Surgery | 2 | 1996 | 235 | 0.060 |
Why?
|
Aging | 1 | 2008 | 716 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 102 | 0.050 |
Why?
|
Lactic Acid | 1 | 2023 | 92 | 0.050 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2009 | 576 | 0.050 |
Why?
|
Radiography | 3 | 2012 | 809 | 0.050 |
Why?
|
Antigens, Polyomavirus Transforming | 2 | 2015 | 47 | 0.050 |
Why?
|
Brain Chemistry | 1 | 2002 | 122 | 0.050 |
Why?
|
Wnt Signaling Pathway | 1 | 2023 | 97 | 0.050 |
Why?
|
Motion | 1 | 2022 | 93 | 0.050 |
Why?
|
Models, Statistical | 3 | 2011 | 575 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2023 | 369 | 0.050 |
Why?
|
Rhabdomyosarcoma | 1 | 2002 | 42 | 0.050 |
Why?
|
beta Catenin | 1 | 2023 | 266 | 0.050 |
Why?
|
Pregnancy | 2 | 2023 | 3011 | 0.050 |
Why?
|
Cell Hypoxia | 1 | 2022 | 170 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 340 | 0.050 |
Why?
|
Lipopolysaccharides | 1 | 2023 | 293 | 0.050 |
Why?
|
Tibial Arteries | 1 | 2021 | 5 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2023 | 8217 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2009 | 1547 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 193 | 0.050 |
Why?
|
Fibula | 1 | 2021 | 32 | 0.050 |
Why?
|
Mice, Inbred C3H | 1 | 2020 | 371 | 0.040 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2021 | 93 | 0.040 |
Why?
|
Regional Blood Flow | 1 | 2020 | 198 | 0.040 |
Why?
|
Young Adult | 3 | 2017 | 6294 | 0.040 |
Why?
|
Indicator Dilution Techniques | 1 | 2019 | 9 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 369 | 0.040 |
Why?
|
Cytological Techniques | 1 | 1999 | 30 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 1940 | 0.040 |
Why?
|
Microwaves | 1 | 1999 | 36 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 1999 | 198 | 0.040 |
Why?
|
Ultrasonography, Interventional | 1 | 1999 | 123 | 0.040 |
Why?
|
Image-Guided Biopsy | 1 | 2018 | 68 | 0.040 |
Why?
|
Fructose | 1 | 2018 | 36 | 0.040 |
Why?
|
Weaning | 1 | 2017 | 25 | 0.040 |
Why?
|
Radial Artery | 1 | 2017 | 33 | 0.040 |
Why?
|
Random Allocation | 1 | 2018 | 328 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 181 | 0.040 |
Why?
|
Adiposity | 1 | 2017 | 76 | 0.040 |
Why?
|
Pressure | 1 | 2017 | 165 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2001 | 1108 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2023 | 2479 | 0.030 |
Why?
|
Time | 1 | 2016 | 76 | 0.030 |
Why?
|
Thermal Conductivity | 1 | 1996 | 3 | 0.030 |
Why?
|
Sonication | 1 | 1996 | 4 | 0.030 |
Why?
|
Mathematics | 1 | 1996 | 191 | 0.030 |
Why?
|
Auditory Perception | 1 | 1997 | 98 | 0.030 |
Why?
|
Simian virus 40 | 1 | 2015 | 35 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2008 | 2347 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2002 | 1194 | 0.030 |
Why?
|
Edema | 1 | 2014 | 70 | 0.030 |
Why?
|
Color | 1 | 2014 | 85 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2014 | 121 | 0.030 |
Why?
|
Mammography | 1 | 2017 | 471 | 0.030 |
Why?
|
Cells, Cultured | 1 | 1999 | 2880 | 0.030 |
Why?
|
Perfusion | 1 | 2014 | 235 | 0.030 |
Why?
|
Rabbits | 1 | 2014 | 638 | 0.030 |
Why?
|
Streptozocin | 1 | 2012 | 55 | 0.030 |
Why?
|
Signal Transduction | 1 | 2023 | 3376 | 0.030 |
Why?
|
Adenoviridae | 1 | 2013 | 349 | 0.030 |
Why?
|
Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2012 | 101 | 0.020 |
Why?
|
Postoperative Period | 1 | 2012 | 302 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 470 | 0.020 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2012 | 191 | 0.020 |
Why?
|
Risk Assessment | 1 | 2019 | 2302 | 0.020 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 46 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2012 | 370 | 0.020 |
Why?
|
Fluorescence | 1 | 2011 | 103 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2011 | 240 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 1237 | 0.020 |
Why?
|
Intestines | 1 | 2013 | 416 | 0.020 |
Why?
|
Ileum | 1 | 2011 | 160 | 0.020 |
Why?
|
Angiography | 1 | 2011 | 208 | 0.020 |
Why?
|
Extremities | 1 | 2011 | 169 | 0.020 |
Why?
|
Biological Transport | 1 | 2010 | 401 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2015 | 2002 | 0.020 |
Why?
|
Regression Analysis | 1 | 2010 | 590 | 0.020 |
Why?
|
Deuterium | 1 | 2008 | 33 | 0.020 |
Why?
|
Spectrophotometry | 1 | 2008 | 108 | 0.020 |
Why?
|
Microscopy | 1 | 2008 | 87 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 428 | 0.020 |
Why?
|
Dogs | 2 | 1999 | 704 | 0.020 |
Why?
|
Endoscopy | 1 | 2011 | 348 | 0.020 |
Why?
|
Radiology | 1 | 2008 | 199 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 1710 | 0.020 |
Why?
|
Inflammation | 1 | 2011 | 971 | 0.020 |
Why?
|
Kidney | 2 | 1999 | 1146 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 3211 | 0.010 |
Why?
|
Prognosis | 1 | 2009 | 3776 | 0.010 |
Why?
|
Ribs | 1 | 1999 | 46 | 0.010 |
Why?
|
Lung | 1 | 1999 | 1258 | 0.010 |
Why?
|